adults underwent allogeneic PBSC transplantation. The first 49 received tacrolimus monotherapy as GVHD prophylaxis and the subsequent 48 received combination therapy. The median follow-up for survivors was 67 months. Compared to combination therapy, tacrolimus monotherapy resulted in enhanced neutrophil engraftment, shortened hospitalization, comparable rates of GVHD, and equivalent 100-day survival. The CI of grades II-IV acute GVHD was 35% with tacrolimus and 23% with the combination (P ¼ 0.19). The CI of III-IV GVHD was 22% for tacrolimus and 19% for the combination. CI of chronic GVHD was similar between the two groups (P ¼ 0.5). Patients with good-risk disease had superior overall survival (OS) when compared to those with poor-risk features (Po0.001). Within the good-risk disease category, patients receiving methotrexate had a trend towards improved OS (P ¼ 0.07). Multivariate analysis indicated good-risk disease status and methotrexate were independently associated with improved OS, progression-free survival (PFS), and relapse. In addition, patients developing chronic GVHD had a significantly reduced risk of relapse and improved PFS. Early clinical trials of tacrolimus alone or in combination with short-course methotrexate (15 mg/m 2 on day 1, 10 mg/ m 2 on day 3, 6, and 11) demonstrated efficacy in terms of graft-versus-host disease (GVHD) prophylaxis, while also revealing nephrotoxicity similar to cyclosporine.
tacrolimus; methotrexate
In the early 1990s, tacrolimus was introduced as a potent macrolide immunosuppressant, capable of 100 times greater in vitro inhibition of T cells than cyclosporine. 1 Early clinical trials of tacrolimus alone or in combination with short-course methotrexate (15 mg/m 2 on day 1, 10 mg/ m 2 on day 3, 6, and 11) demonstrated efficacy in terms of graft-versus-host disease (GVHD) prophylaxis, while also revealing nephrotoxicity similar to cyclosporine. [2] [3] [4] Subsequently, three prospective randomized trials (in HLAidentical siblings and/or unrelated donors) have confirmed the superiority of tacrolimus and short-course methotrexate over cyclosporine and methotrexate in significantly decreasing the incidence of acute GVHD. [5] [6] [7] When age, disease, and disease status at the time of transplant were considered for the largest of the randomized trials, there was no adverse effect on relapse or survival due to the GVHD prophylaxis regimen employed. 5, 8 To date, there have been no reported trials comparing tacrolimus as monotherapy to the combination of tacrolimus with either short-course or minidose methotrexate for prophylaxis of acute GVHD. In an effort to determine the role of methotrexate when used in conjunction with tacrolimus in the prevention of acute GVHD, we retrospectively evaluated two sequential GVHD prophylaxis regimens for patients with hematologic malignancies receiving a sibling donor peripheral blood stem cell (PBSC) transplant. The first regimen consisted of tacrolimus as monotherapy in the setting of predominantly advanced hematologic malignancies, in an effort to maintain graftversus-tumor effects while employing a potent immunosuppressant for GVHD prophylaxis. It was hoped that patients with high-risk features might especially benefit by avoiding any additional immunosuppression that might contribute to relapse, as well as avoiding the increased toxicity and delayed engraftment associated with shortcourse methotrexate. The second regimen employed tacrolimus and minidose methotrexate (5 mg/m 2 on day 1, 3, 6, and 11) for GVHD prophylaxis, and included both goodrisk and advanced stage diseases. The combination of tacrolimus and minidose methotrexate has been safely administered in the setting of related and unrelated bone marrow transplantation, without compromise in the efficacy of GVHD prevention. [9] [10] [11] We herein report longterm outcomes using two sequential GVHD prophylaxis strategies after sibling donor PBSC transplantation (PBSCT), evaluating the incidence of acute and chronic GVHD, and examining the contribution of chronic GVHD to relapse and survival.
Materials and methods

Subjects and preparative regimens
Adults with histologically diagnosed hematologic malignancies undergoing allogeneic PBSCT received one of two sequential GVHD prophylaxis regimens. Younger patients (agep55 years) with CML in chronic phase were specifically excluded from receiving tacrolimus alone for GVHD prophylaxis. Preparative regimens, administered according to diagnosis, are listed in Table 1. 12-15 All patients gave written informed consent. The studies were conducted with the approval of the Institutional Review Board at the University of Michigan Medical Center.
Donor leukapheresis, recipient transplant
Allogeneic donors received granulocyte colony-stimulating factor (G-CSF; 8 mg/kg s.c. b.i.d.) for 4 days, followed by leukapheresis on the fifth. The harvest target was 5.0 Â 10 6 CD34 þ /kg PBSC. PBSC were infused 48-72 h after completion of chemotherapy (day 0). G-CSF (5 mg/kg/day s.c.) was begun on day 6, excluding patients with CML, and continued until an absolute neutrophil count (ANC) X1000/ml was achieved.
GVHD prophylaxis, diagnosis, and treatment
All patients received tacrolimus (0.03 mg/kg/day calculated by lean body weight) by continuous intravenous infusion beginning on day À1. After recovery from the acute toxicities of transplant, patients began oral tacrolimus (at an i.v.:p.o. conversion ratio of 1:4, divided into two equal doses every 12 h). Tacrolimus levels were obtained twice weekly for the first 8 weeks, and adjusted to maintain whole blood levels of 10-20 ng/ml. Dose reductions were performed if toxicity (renal insufficiency, hyperkalemia, neuropathy) was observed. Beginning day 56, the dose was tapered 20% every 4 weeks and discontinued on day 180 if GVHD was not documented. In the first cohort, patients received tacrolimus alone for GVHD prophylaxis.
Minidose methotrexate (5 mg/m 2 intravenous bolus on day 1, 3, 6, and 11) was given in addition to tacrolimus to the second cohort of patients. 10 The decision to administer each dose of methotrexate was determined by the severity of mucositis, the amount of weight gain, the presence of third-spacing, and renal and liver functions on the day the drug was due. 16 Acute and chronic GVHD were diagnosed and graded according to consensus criteria. 17, 18 Patients who developed acute GVHD were treated initially with methylprednisolone (2 mg/kg/day) in addition to tacrolimus. Chronic GVHD was evaluated in those who survived at least 100 days, and treated as clinically indicated.
Definitions and statistical analysis
Disease status was coded as good (complete response or CML in chronic phase) or poor (less than complete response or CML in accelerated or blast phase) risk as determined at the time of transplantation. Time to hematologic reconstitution was measured from day 0 to the first of three consecutive measurements of an ANC X500/ml and a platelet count X20 000/ml, independent of transfusions.
Overall (OS) and progression-free survivals (PFS) were defined as the time from day of transplant (day 0) to the day of death or disease progression, respectively. OS, PFS, and relapse were estimated by the Kaplan-Meier productlimit method. 19 Cumulative incidence estimates for acute and chronic GVHD were determined using the methodology of Gooley et al. 20 The log-rank test was used to compare differences between patient subgroups. Cox regression was used to assess the association of subject characteristics with OS, PFS, and relapse. Categorical data were assessed for association using w 2 or Fisher's exact tests. Continuous variables between subgroups were compared using the Student's t-test. All P-values were two-sided, and a P-value less than 0.05 was considered significant.
Results
Characteristics of patients and donors (Table 1) From April 1996 to April 1998, 97 patients underwent allogeneic PBSCT. The first cohort of 49 patients received tacrolimus alone as GVHD prophylaxis, while the subsequent 48 received both tacrolimus and methotrexate. The median duration of follow-up for surviving patients was 67 months post-transplant (range, 15-83 months).
Age, gender, and stem cell doses were similar among the tacrolimus and tacrolimus/methotrexate groups. The distribution of good-vs poor-risk patients favored the tacrolimus/methotrexate group (P ¼ 0.06). There were more CML-CP patients receiving tacrolimus/methotrexate (P ¼ 0.03), which was reflected in the preparative regimens employed (Po0.01). All five patients who received PBSC from a one-antigen disparate sibling were in the tacrolimus/ methotrexate group (P ¼ 0.03).
Engraftment and hospitalization
Three patients died before neutrophil and six before platelet engraftment. Neutrophil engraftment was quicker in those patients receiving tacrolimus as monotherapy, occurring a median of 10.9 days (range 7-32) as compared to 12.3 days (range 9-21) for those receiving tacrolimus/methotrexate (P ¼ 0.04). Platelet recovery for the tacrolimus and tacrolimus/methotrexate groups occurred with a median of 13.4 (range 6-33) and 14.0 (range 8-30) days, respectively (P ¼ 0.6). There was no difference in the severity of mucositis for patients receiving tacrolimus alone or tacrolimus/methotrexate (P ¼ 0.37). The length of hospitalization after PBSC infusion favored the tacrolimus group (median 14 vs 17 days, P ¼ 0.07).
Acute and chronic GVHD
The cumulative incidence of grades II-IV acute GVHD was 29% (95% CI, 21-39%) for the entire group: 35% (95% CI, 22-49%) with tacrolimus alone and 23% (95% CI, 13-36%) with the combination (P ¼ 0.19) (Figure 1) . Of the 49 patients receiving tacrolimus, 17 developed grades II-IV acute GVHD and 10 of these were grades III-IV. In the tacrolimus/methotrexate group, 11 of 48 patients developed grades II-IV acute GVHD and eight of these were grades III-IV. The cumulative incidence of grades III-IV acute GVHD was 21% (95% CI, 13-29%) for the entire group: 22% (95% CI, 12-37%) for patients receiving tacrolimus alone and 19% (95% CI, 8-32%) for those receiving tacrolimus/methotrexate (P ¼ 0.6). Of the five patients receiving a mismatched transplant, three developed acute GVHD (two grades II and one grade III-IV) despite tacrolimus/methotrexate prophylaxis. Exclusion of those five patients did not significantly reduce the incidence of acute GVHD in favor of the combination.
In the group receiving methotrexate, 34 of 47 (72%) patients received X75%, nine (19%) received 50-74%, and four received o50% of the planned doses of methotrexate. There was no correlation between dosage of methotrexate actually delivered (o75% vs X75% of intended full dose) and the incidence of grades II-IV acute GVHD (P ¼ 0.27).
A total of 75 patients were alive without relapse at day 100 post-transplant; 45 of them developed chronic GVHD, a cumulative incidence at 1 year of 50% (95% CI, 41-64%). The probability of developing chronic GVHD was not influenced by the addition of methotrexate for GVHD prophylaxis: 53% (95% CI, 42-72%) for those receiving tacrolimus monotherapy vs 50% (95% CI, 34-66%) for the combination (P ¼ 0.5) (Figure 2) . Of 36 patients, 22 receiving tacrolimus developed chronic GVHD (10 limited, 12 extensive disease), as did 23 (of 38) in the tacrolimus/ methotrexate group (11 limited, 12 extensive disease). 
Survival and relapse
Five (5%) patients died before day 30 of treatment-related toxicity, therefore 92 were evaluable for survival and response duration. The median OS and PFS for the whole group were 32.8 and 15.7 months, respectively. Kaplan-Meier estimates of OS and PFS at 100 days were 79% (95% CI, 72-88%) and 77% (95% CI, 69-86%), respectively. The addition of methotrexate had no influence on 100-day survival. KaplanMeier estimates of OS and PFS at 1 year were 60% (95% CI, 51-70%) and 56% (95% CI, 47-67%), respectively. As expected, patients with good-risk disease had superior OS when compared to those with poor-risk features (Po0.001).
Within the good-risk group, patients receiving methotrexate had a trend toward improved OS (P ¼ 0.07) (Figure 3) . Similarly within the poor-risk group, those receiving methotrexate had a trend toward improved survival (P ¼ 0.13). A total of 55 (57%) patients have died and the causes of death are listed in Table 2 . Of 36 deaths in the tacrolimus group, 14 (39%) were due to regimen-related toxicity, compared to four of 19 deaths (21%) in the tacrolimus/ methotrexate group. A total of 23 patients had disease progression (14 of 49 receiving tacrolimus; nine of 48 receiving the combination), for an estimated 1-year relapse rate of 21% (95% CI, 11-30%) for the whole group. Twentyone of the 23 subsequently died from disease progression. Relapse at 1 year was estimated at 7% (95% CI, 0-15%) for those receiving tacrolimus/methotrexate, and 36% (95% CI, 18-50%) for those receiving tacrolimus alone (P ¼ 0.07).
Multivariate analysis (Table 3) A standard Cox regression model was used to evaluate the rates of OS, PFS, and relapse for the 77 subjects alive at day 100, adjusting for the following characteristics: age, disease status (very good risk included CML-CP only, good risk included complete responders at the time of transplant, and poor risk included all others), methotrexate use, acute GVHD (treated as a fixed variable), and chronic GVHD (treated as a time-dependent covariate). Since patients with CML-CP were over-represented in the tacrolimus/methotrexate group, and as a favorable prognostic population could potentially influence outcome, those patients were treated as a unique variable (very good-risk category) in the multivariate analysis.
Even after adjusting for CML-CP, both good-risk disease status (complete responders) and the addition of methotrexate were independently associated with improved OS, PFS, and relapse. Furthermore, patients developing chronic GVHD had a significantly reduced risk of relapse and improved PFS when compared to those not developing chronic GVHD. Age and the development of acute GVHD did not influence outcome.
Discussion
In this study, we explored the short-term efficacy as well as the long-term outcomes of two sequential GVHD prophy- 21 to date only one trial has been published examining tacrolimus alone for GVHD prophylaxis in related allogeneic transplantation. 2 This present analysis is the largest using allogeneic sibling donor PBSCT.
The addition of minidose methotrexate to tacrolimus did not result in a statistically significant reduction in either the incidence of grades II-IV (35% for tacrolimus vs 23% for tacrolimus/methotrexate; P ¼ 0.19) or III-IV acute GVHD. It is likely that the size of the two treatment groups was insufficient to detect small differences in the rate of acute GVHD. In addition, the low doses of methotrexate employed might not have contributed a substantive immunosuppressive effect after PBSCT to result in reduction of acute GVHD. With the use of cyclosporine, previous studies have shown that the addition of shortcourse methotrexate significantly decreased the incidence of acute GVHD. 22 In our study, however, there was no correlation between the dosage of methotrexate actually delivered and the incidence of grades II-IV acute GVHD seen (P ¼ 0.27). This observation contrasts with that reported after cyclosporine and short-course methotrexate prophylaxis, which revealed that reduction to o80% of the scheduled dose of methotrexate independently increased the risk of acute GVHD. 23 The more potent immunosuppressive activity of tacrolimus over cyclosporine may lessen the need for the addition of methotrexate to the GVHD prophylaxis regimen.
In the three prospective randomized trials confirming the superiority of tacrolimus and short-course methotrexate over cyclosporine and methotrexate, the contribution of methotrexate was never defined. [5] [6] [7] The incidence of acute GVHD in each patient cohort in this analysis was comparable to that seen with tacrolimus/methotrexate prophylaxis with marrow support, 5 as well as with PBSC transplants employing cyclosporine and short-course methotrexate for GVHD prophylaxis. [24] [25] [26] [27] The comparable rates of acute GVHD between these studies and both cohorts in our study suggest that either tacrolimus alone or with minidose methotrexate provides sufficient immunosuppressive activity in PBSCT. Three single institution trials have evaluated tacrolimus with varying doses and schedules of methotrexate for related allogeneic transplantation. 4, 11, 28 Including the data presented here, the incidence of grades II-IV (8%-59%) and III-IV (0%-17%) acute GVHD varied considerably from study to study. These differences most likely reflect a heterogeneous patient population, disparate numbers of one-antigen mismatched donors, use of PBSC or marrow source, and doses of methotrexate administered.
The 1-year incidence of chronic GVHD observed in this study, 53% for patients who received tacrolimus alone and 50% for those receiving tacrolimus/methotrexate, is similar to that reported elsewhere for PBSC recipients. 24, 27, 29 The risk of chronic GVHD for patients receiving G-CSFmobilized PBSC has been reported to be higher than for marrow grafts by some investigators 25, 29, 30 but not by others. 26, 27 The role of methotrexate in the prevention of chronic GVHD after PBSCT is likewise undefined. In a retrospective analysis of PBSCT, patients receiving tacrolimus and methotrexate for GVHD prophylaxis had a lower incidence of extensive chronic GVHD when compared with either tacrolimus/methylprednisolone or cyclosporine/methotrexate. 31 However, the development of chronic GVHD may be heavily influenced by the CD34 þ and CD3 þ cell doses infused. The higher cell doses (48 Â 10 6 CD34 þ /kg) used in PBSCT may offset any role that the prophylactic regimens may play. 32 The presence of chronic GVHD in our study was associated with a significant reduction in relapse with improved PFS and a strong trend in favor of OS. Data are limited regarding the contribution of chronic GVHD to relapse and survival after allogeneic PBSCT. However in the setting of marrow transplantation, the association of chronic GVHD with improved survival is well recognized. 33 Three randomized studies comparing PBSC and marrow have suggested a lower rate of relapse for a subset of patients receiving PBSC. 26, 27, 34 The potential graft-versustumor effects in the setting of PBSCT and chronic GVHD need further study. However, the long-term sequelae of chronic GVHD after PBSCT, with the attendant effects on quality of life and survival, remain unknown.
As expected, the long-term OS and PFS favored patients who had good-risk features at the time of transplant. Within both the good-risk and poor-risk disease category, patients who received methotrexate had a trend toward improved OS (Figure 3 ). After adjusting for variables such as disease (CML-CP as unique factor), disease status, age, and the presence of GVHD, the addition of methotrexate proved to be an independent factor in improving OS, relapse, and PFS. This improvement occurred despite a lack of influence by methotrexate on the development of acute or chronic GVHD. Why such a survival benefit should occur for patients receiving methotrexate is speculative. It is unlikely that the small doses of methotrexate given provided antitumor activity. The survival benefit observed for the group receiving tacrolimus/methotrexate may reflect a far more favorable tumor group than could be accounted for in our multivariate analysis. The monotherapy group, with more advanced disease requiring more intensive preparative regimens, experienced greater regimen-related mortality and deaths from disease progression (27 deaths vs 12 for the combination). The presence of chronic GVHD, regardless of methotrexate, likewise played a role in the favorable outcomes observed.
In the absence of a prospective randomized trial, it is difficult to delineate the role of methotrexate (either short course or minidose) when combined with tacrolimus for the prevention of acute GVHD. In retrospective evaluation, a mixed patient population may receive varying conditioning regimens with different dose-limiting toxicities, resulting in heterogeneity in methotrexate doses actually delivered. Owing to its potency as an immunosuppressant, tacrolimus may serve as a useful platform on which to add newer immunosuppressive agents such as etanercept or mycophenolate mofetil for the prevention of acute GVHD after allogeneic PBSCT. Our data would support such a strategy. Caution must be used with tacrolimus monotherapy. Despite similar rates of acute and chronic GVHD, our long-term data showed improved survival for patients who received combination therapy with tacrolimus and methotrexate for the prevention of acute GVHD.
